January 2,2021 New Delhi
The subject expert committee (SEC) is all set to authorise the use of Covishield, the vaccine to fight Covid-19, for emergency use in the country, sources said on Friday.
The application will now be forwarded to the drug regulator (DCGI) for final approval before the innoculations begin. The SEC is an expert panel on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO). This vaccine has been developed by AstraZeneca and will be produced here by Serum Institute of India (SII).
On Friday, after studying SII’s application, the SEC also started reviewing the EUA application by Bharat Biotech for its Covid-19 vaccine — Covaxin — but is yet to take a final decision on the matter, sources said.